PD-L1 Antibody – 149Sm

Catalog: 714902

Clone: E1L3N (PD-L1) & 1D4-C5 (Biotin)

Isotype: Rabbit IgG (PD-L1) & Mouse IgG2a (Biotin)

Reactivity: Human* (PD-L1)

Application: MIBI-FFPE

Storage: Supplied in antibody stabilizer with 0.05% sodium azide. Store at 4°C

PDL1-IHC-staining-FFPE-human-diffuse-large-B-cell-lymphoma

IHC: PD-L1 antibody staining of FFPE human thymus

PDL1-Ionpath-MIBI-staining-FFPE-human-diffuse-large-B-cell-lymphoma

MIBI: PD-L1 antibody staining (amplified with anti-Biotin, cyan) of FFPE human thymus, counterstained with dsDNA (magenta)

IHC: PD-L1 antibody staining of FFPE human lymphoma

PDL1-Ionpath-MIBI-staining-FFPE-human-thymic-SCC

MIBI: PD-L1 antibody staining (amplified with anti-Biotin, cyan) of FFPE human lymphoma, counterstained with dsDNA (magenta)

Background: Programmed cell death 1 ligand 1 (PD-L1, CD274) binds to PD-1 and inhibits T cell activation. APCs, activated T cells, and tissues including placenta, heart, and lung can express PD-L1. PD-L1 is expressed in cancer as a means for cancerous cells to inhibit immune responses. PD-L1 has been detected for several tumor types including melanoma, lung, ovary, colon, breast, and renal cell carcinomas. PD-L1 expression in cancer is associated with tumor infiltrating lymphocytes, which mediate PD-L1 expression through the release of interferon gamma. Inhibition of the PD-1－PD-L1 axis has been an active area of clinical research with several approved drugs for multiple indications.

Validation: Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIscope analysis using the appropriate positive and negative tissue field of views.

MIBI technology: Learn more about MIBI™ Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.

References

Wimberly, H. et al. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res. 2015; 3(4): 326-332.
Bindels, S. et al. Regulation of PD-L1 by SIP1 in human epithelial breast tumor cells. Oncogene. 2006; 25:4975–4985.

* Conjugate tested on human tissue.

Download Technical Data Sheet

PD-L1 Antibody – 149Sm

We are using cookies on our website